company background image
PCSA logo

Processa Pharmaceuticals NasdaqCM:PCSA Stock Report

Last Price

US$1.03

Market Cap

US$3.4m

7D

-3.0%

1Y

-93.8%

Updated

09 Dec, 2024

Data

Company Financials +

Processa Pharmaceuticals, Inc.

NasdaqCM:PCSA Stock Report

Market Cap: US$3.4m

PCSA Stock Overview

A clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. More details

PCSA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Processa Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Processa Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.03
52 Week HighUS$17.40
52 Week LowUS$0.85
Beta0.58
11 Month Change-6.11%
3 Month Change-21.16%
1 Year Change-93.82%
33 Year Change-98.81%
5 Year Change-99.51%
Change since IPO-99.97%

Recent News & Updates

Recent updates

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Dec 12
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Oct 20
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Aug 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Jul 07
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Jan 20
We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Aug 26
Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Jun 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Mar 15
What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

Jan 29

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Jan 20
How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Shareholder Returns

PCSAUS PharmaceuticalsUS Market
7D-3.0%0.9%1.0%
1Y-93.8%13.4%32.4%

Return vs Industry: PCSA underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.

Return vs Market: PCSA underperformed the US Market which returned 32.4% over the past year.

Price Volatility

Is PCSA's price volatile compared to industry and market?
PCSA volatility
PCSA Average Weekly Movement10.7%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: PCSA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PCSA's weekly volatility has decreased from 29% to 11% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201113George Ngwww.processapharmaceuticals.com

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.

Processa Pharmaceuticals, Inc. Fundamentals Summary

How do Processa Pharmaceuticals's earnings and revenue compare to its market cap?
PCSA fundamental statistics
Market capUS$3.37m
Earnings (TTM)-US$11.53m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PCSA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$11.53m
Earnings-US$11.53m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.53
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PCSA perform over the long term?

See historical performance and comparison